10x Genomics and Fred Hutch collaborate to advance single cell and spatial applications across solid tumors and blood cancers

N-Power Medicine and New York Cancer & Blood Specialists partner to reduce size of oncology clinical trials and accelerate new therapies

N-Power Medicine and New York Cancer & Blood Specialists announced a strategic partnership to accelerate the generation of N-Power’s Prospective External Control Arms. This approach is designed to reduce the size of oncology clinical trials and bring new therapies to patients years sooner.

October 16, 2026

Vol.52 No.38

Clinical Roundup

Limiting sugar intake could reduce allogeneic hematopoietic cell transplant side effects

Eating less sugar could protect the microbiome during antibiotic treatment, according to a study led by researchers at City of Hope. The study followed patients with blood cancer who were going through an intensive treatment called allogeneic hematopoietic cell transplant. This population is at particularly high risk for severe gut microbiome disruption and associated side effects.

October 02, 2026

Vol.52 No.36

Cancer Policy

Letai shares weekly musings in NCI’s new “Tuesdays with Tony” series

This summer, NCI launched a weekly social media series hosted by Director Anthony Letai.

September 18, 2026

Vol.52 No.34

In Brief

Andrew Hsieh named Larry and Virginia Gordon Endowed Chair in Prostate and Bladder Cancer Research at Fred Hutch

Andrew Hsieh, who serves as the associate director of Fred Hutch’s Human Biology Division, has been named the inaugural holder of the Larry and Virginia Gordon Endowed Chair in Prostate and Bladder Cancer Research.

September 11, 2026

Vol.52 No.33

In Brief

Lawrence Fong appointed senior vice president and director of the Fred Hutch Translational Science and Therapeutics Division

Lawrence Fong was appointed senior vice president and director of Fred Hutch’s Translational Science and Therapeutics Division, effective Dec. 1.

September 11, 2026

Vol.52 No.33

Clinical Roundup

Blood cancer patients may have broader stem cell donor options than previously thought, ACCESS trial shows

Blood cancer patients who cannot find a closely matched stem cell donor may have more transplant options than previously thought.

September 11, 2026

Vol.52 No.33

10x Genomics and Fred Hutch collaborate to advance single cell and spatial applications across solid tumors and blood cancers

YOU MAY BE INTERESTED IN

N-Power Medicine and New York Cancer & Blood Specialists partner to reduce size of oncology clinical trials and accelerate new therapies

Limiting sugar intake could reduce allogeneic hematopoietic cell transplant side effects

Letai shares weekly musings in NCI’s new “Tuesdays with Tony” series

Andrew Hsieh named Larry and Virginia Gordon Endowed Chair in Prostate and Bladder Cancer Research at Fred Hutch

Lawrence Fong appointed senior vice president and director of the Fred Hutch Translational Science and Therapeutics Division

Blood cancer patients may have broader stem cell donor options than previously thought, ACCESS trial shows

Renew today!

Subscriber content

Never miss an issue!

Login